|
|
|
21.08.25 - 09:18
|
Qlife together with Birmingham Women′s and Children′s NHS Foundation Trust achieve positive results for its rare disease self-test PHE product (Cision)
|
|
|
Gothenburg, Sweden - Qlife Holding AB (“Qlife” or the “Company”) announces that it has finalized its clinical study for children and young people under 18 years of age. The study was focused on the self-test at-home aspect and the comparison of data to standard of care methodology DBS-cards (Dried Blood Spots). The study and the enrollment were completed under the leadership of Professor Anita MacDonald, Professor in Dietetics at Birmingham Women's and Children's NHS Foundation Trust.
Summary of results:
· High concordance between Egoo PHE Test results and the Dry Blood Spot (DBS)...
|
|
|
21.08.25 - 08:36
|
Qlife together with Birmingham Women′s and Children′s NHS Foundation Trust achieve positive results for its rare disease self-test PHE product (Cision)
|
|
|
Gothenburg, Sweden - Qlife Holding AB (“Qlife” or the “Company”) announces that it has finalized its clinical study for children and young people under 18 years of age. The study was focused on the self-test at-home aspect and the comparison of data to standard of care methodology DBS-cards (Dried Blood Spots). The study and the enrollment were completed under the leadership of Professor Anita MacDonald, Professor in Dietetics at Birmingham Women's and Children's NHS Foundation Trust.
Summary of results:
· High concordance between Egoo PHE Test results and the Dry Blood Spot (DBS)...
|
|
|
|
|
19.08.25 - 03:03
|
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program (GlobeNewswire EN)
|
|
|
SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce that it entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with R.F. Lafferty & Co., Inc. (the “Agent”), as the sales agent....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.07.25 - 14:33
|
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025 (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, July 30, 2025, to review the company's second quarter 2025 financial results and provide business updates....
|
|
|
|
|
|
|
|
|
|
|
25.06.25 - 12:51
|
China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange (GlobeNewswire EN)
|
|
|
SHENZHEN, CHINA, June 25, 2025 (GLOBE NEWSWIRE) -- The board of directors of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) announces the proposed secondary listing of the Company's ordinary shares (“Shares”) on the Singapore Exchange Securities Trading Limited (the “SGX-ST”) by way of introduction (the “Proposed Secondary Listing”). The Proposed Secondary Listing, if proceeded, will not involve issuance of new shares, and the Shares will continue to be primarily listed and traded on the Hong Kong Stock Exchange thereafter....
|
|
|
|
|
|
|
|
|
05.06.25 - 07:15
|
Research: UOB Kay Hian Lifts HANSOH PHARMA's TP to HKD40 w/ Buy Rating (AAStocks)
|
|
|
According to a report issued by UOB Kay Hian, HANSOH PHARMA (03692.HK) has received approval for two new indications for Ameile and market approval for NSCLC indication in the UK.Meanwhile, HANSOH PHARMA's Hengmeida, which is used for the treatment of candidiasis, has been granted a drug registration certificate by China'......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
